Siga to Contend With Loss to PharmAthene Via Bankruptcy Plan
Siga Technologies Inc. is expected to say by today what its loss to PharmAthene Inc. in a long-running court fight means for its future, Dow Jones Daily Bankruptcy Review reported today. Last week, the Delaware Supreme Court upheld a $113 million damages award against Siga, which makes an antiviral drug that shows promise against smallpox. PharmAthene, which won the damages award, holds a seat on the official committee of unsecured creditors in Siga's chapter 11 case. Siga is supposed to file a report today with the bankruptcy court that explains its thinking on how to settle up with PharmAthene.